Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

NCT02531438 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

774

Enrollment

INDUSTRY

Sponsor class

Conditions

Bacterial Pneumonia
Community-Acquired Infections

Interventions

DRUG: Omadacycline
DRUG: Moxifloxacin

Sponsor

Paratek Pharmaceuticals Inc